VKTX - Viking Therapeutics Stock Price, News & Analysis

$2.93 0.16 (5.78 %)
(As of 11/23/2017 04:25 AM ET)
Previous Close$2.77
Today's Range$2.71 - $2.97
52-Week Range$0.88 - $3.24
Volume311,000 shs
Average Volume310,981 shs
Market Capitalization$83.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:VKTX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio1.20%
Quick Ratio1.20%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book36.63

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.83)
Net Income$-14,730,000.00
Net MarginsN/A
Return on Equity-330.42%
Return on Assets-144.29%

Miscellaneous

Employees12
Outstanding Shares28,500,000

Frequently Asked Questions for Viking Therapeutics (NASDAQ:VKTX)

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.03. View Viking Therapeutics' Earnings History.

Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2017?

3 brokerages have issued 12-month price objectives for Viking Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Viking Therapeutics' stock price to reach $5.67 in the next year. View Analyst Ratings for Viking Therapeutics.

Who are some of Viking Therapeutics' key competitors?

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:

  • Lawson Macartney Ph.D., Chairman of the Board (Age 57)
  • Brian W. Lian Ph.D., President, Chief Executive Officer, Director
  • Michael Morneau, Chief Financial Officer (Age 49)
  • Amy Broidrick, Senior Vice President - Corporate Development
  • Gregory S. Zante CPA, Vice President - Finance and Operations (Age 42)
  • Catherine Lee Kelleher M.D., Vice President - Clinical Development
  • Matthew W. Foehr, Director (Age 44)
  • Charles A. Rowland Jr., Director (Age 58)
  • Matthew Singleton, Independent Director
  • Stephen W. Webster, Independent Director (Age 56)

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Who owns Viking Therapeutics stock?

Viking Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (1.02%) and Citadel Advisors LLC (0.20%). View Institutional Ownership Trends for Viking Therapeutics.

Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?

Viking Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Citadel Advisors LLC. View Insider Buying and Selling for Viking Therapeutics.

How do I buy Viking Therapeutics stock?

Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of Viking Therapeutics stock can currently be purchased for approximately $2.93.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $83.50 million. The biotechnology company earns $-14,730,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Viking Therapeutics employs 12 workers across the globe.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 El Camino Real Ste 250, SAN DIEGO, CA 92130-3093, United States. The biotechnology company can be reached via phone at +1-858-7044660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (VKTX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Viking Therapeutics (NASDAQ:VKTX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.67 (93.40% upside)

Consensus Price Target History for Viking Therapeutics (NASDAQ:VKTX)

Price Target History for Viking Therapeutics (NASDAQ:VKTX)

Analysts' Ratings History for Viking Therapeutics (NASDAQ:VKTX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Roth CapitalInitiated CoverageBuy -> Buy$5.00N/AView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy -> Buy$7.00N/AView Rating Details
10/4/2017Maxim GroupReiterated RatingBuy$5.00N/AView Rating Details
8/11/2016LaidlawLower Price TargetBuy$20.00 -> $10.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Viking Therapeutics (NASDAQ:VKTX)

Earnings by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Earnings History by Quarter for Viking Therapeutics (NASDAQ VKTX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.19)($0.22)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.19)($0.21)ViewListenView Earnings Details
3/21/2017Q4 2016($0.20)($0.18)ViewN/AView Earnings Details
11/10/2016Q316($0.21)($0.20)ViewN/AView Earnings Details
8/10/2016Q2($0.20)($0.22)ViewN/AView Earnings Details
5/10/2016Q1($0.45)($0.40)ViewN/AView Earnings Details
3/8/2016Q415($0.44)($0.56)ViewN/AView Earnings Details
11/5/2015($0.37)($0.53)ViewN/AView Earnings Details
8/13/2015Q215($0.13)($1.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Viking Therapeutics (NASDAQ:VKTX)
2017 EPS Consensus Estimate: ($0.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.20)($0.20)($0.20)
Q3 20172($0.20)($0.19)($0.20)
Q4 20172($0.19)($0.17)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Viking Therapeutics (NASDAQ:VKTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Viking Therapeutics (NASDAQ VKTX)

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 8.84%
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Insider Trades by Quarter for Viking Therapeutics (NASDAQ VKTX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2016Matthew W FoehrDirectorBuy13,000$1.21$15,730.00View SEC Filing  
4/13/2016Matthew W FoehrDirectorBuy20,000$1.24$24,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Viking Therapeutics (NASDAQ VKTX)

Source:
DateHeadline
Viking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth CapitalViking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth Capital
www.americanbankingnews.com - November 21 at 10:33 AM
Viking Therapeutics (VKTX) vs. Its Rivals Head-To-Head AnalysisViking Therapeutics (VKTX) vs. Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - November 14 at 9:48 AM
Viking Therapeutics (VKTX) Buy Rating Reaffirmed at HC WainwrightViking Therapeutics' (VKTX) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 12 at 1:10 PM
VKTX: Data From Phase 2 Trial of VK5211 to be Reported SoonVKTX: Data From Phase 2 Trial of VK5211 to be Reported Soon
finance.yahoo.com - November 12 at 1:10 PM
Viking Therapeutics, Inc. (VKTX) Announces Quarterly  Earnings ResultsViking Therapeutics, Inc. (VKTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 5:36 PM
Viking Therapeutics (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking AlphaViking Therapeutics' (VKTX) CEO Brian Lian on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - November 9 at 9:32 AM
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateViking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 9:32 AM
Analyzing Viking Therapeutics (VKTX) and The CompetitionAnalyzing Viking Therapeutics (VKTX) and The Competition
www.americanbankingnews.com - November 8 at 9:34 PM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 - PR Newswire (press release)
www.prnewswire.com - November 1 at 10:25 AM
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
finance.yahoo.com - November 1 at 10:25 AM
Viking Therapeutics, Inc. (VKTX) Set to Announce Quarterly Earnings on WednesdayViking Therapeutics, Inc. (VKTX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Analyzing Viking Therapeutics (VKTX) and Its CompetitorsAnalyzing Viking Therapeutics (VKTX) and Its Competitors
www.americanbankingnews.com - November 1 at 1:20 AM
Viking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts TargetViking Therapeutics, Positive Clinical Data Across the Pipeline, Analysts Target
finance.yahoo.com - October 31 at 11:48 AM
VKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both CompoundsVKTX: Poster Presentations on VK2809 and VK0214 Highlight Positive Preclinical Data for Both Compounds
finance.yahoo.com - October 28 at 7:51 AM
Viking Therapeutics (VKTX) Announces Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked ... - StreetInsider.comViking Therapeutics (VKTX) Announces Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked ... - StreetInsider.com
www.streetinsider.com - October 24 at 4:16 PM
Viking Therapeutics (VKTX) Announces Results from In Vivo Study of VK2809 - StreetInsider.comViking Therapeutics (VKTX) Announces Results from In Vivo Study of VK2809 - StreetInsider.com
www.streetinsider.com - October 24 at 4:16 PM
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
finance.yahoo.com - October 24 at 12:05 PM
Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid AssociationViking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 23 at 8:56 AM
Viking Therapeutics: What Direction Now For This ~$2.50 Biotech Busted IPO? - Seeking AlphaViking Therapeutics: What Direction Now For This ~$2.50 Biotech 'Busted IPO'? - Seeking Alpha
seekingalpha.com - October 20 at 9:59 AM
Health Care Sector Update for 10/18/2017: VKTX,SPPI,AKTX - NasdaqHealth Care Sector Update for 10/18/2017: VKTX,SPPI,AKTX - Nasdaq
www.nasdaq.com - October 18 at 9:09 PM
VKTX: KOLs Highlight Necessity For Effective Hip Fracture TreatmentVKTX: KOLs Highlight Necessity For Effective Hip Fracture Treatment
finance.yahoo.com - October 12 at 9:51 AM
Viking Therapeutics, Inc. (VKTX) Given "Buy" Rating at Maxim GroupViking Therapeutics, Inc. (VKTX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - October 5 at 2:56 PM
Viking Therapeutics (VKTX) Reports Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-ALD - StreetInsider.comViking Therapeutics (VKTX) Reports Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-ALD - StreetInsider.com
www.streetinsider.com - October 4 at 8:52 AM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD)
finance.yahoo.com - October 4 at 8:52 AM
Corporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park CapitalCorporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park Capital
finance.yahoo.com - October 3 at 2:33 PM
Should You Buy Viking Therapeutics Inc (VKTX) Now?Should You Buy Viking Therapeutics Inc (VKTX) Now?
finance.yahoo.com - September 23 at 10:48 AM
Viking Therapeutics (VKTX) Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in NASH - StreetInsider.comViking Therapeutics (VKTX) Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in NASH - StreetInsider.com
www.streetinsider.com - September 13 at 3:55 PM
VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASHVKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH
finance.yahoo.com - September 13 at 11:02 AM
Viking Therapeutics (VKTX) "Buy" Rating Reaffirmed at Maxim GroupViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - September 11 at 4:31 PM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
finance.yahoo.com - September 11 at 8:20 AM
Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809
www.streetinsider.com - September 8 at 9:59 AM
Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809 - StreetInsider.comViking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809 - StreetInsider.com
www.streetinsider.com - September 7 at 10:53 AM
Viking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809 - StreetInsider.comViking Therapeutics (VKTX) Presents Data from In Vivo Proof-of-Concept Study of VK2809 - StreetInsider.com
www.streetinsider.com - September 7 at 10:53 AM
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
finance.yahoo.com - September 7 at 10:53 AM
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)
finance.yahoo.com - September 7 at 10:53 AM
Viking Therapeutics to Present at Rodman & Renshaws 19th Annual Global Investment Conference - PR Newswire (press release)Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - September 6 at 9:58 AM
Viking Therapeutics to Present at Rodman & Renshaws 19th Annual Global Investment Conference - PR Newswire (press release)Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - September 6 at 9:58 AM
Viking Therapeutics to Present at Rodman & Renshaws 19th Annual Global Investment ConferenceViking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:58 AM
Viking Therapeutics to Present at Rodman & Renshaws 19th Annual Global Investment ConferenceViking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:58 AM
VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17
finance.yahoo.com - August 15 at 8:02 AM
Viking Therapeutics, Inc. (VKTX) Posts Quarterly  Earnings Results, Misses Estimates By $0.02 EPSViking Therapeutics, Inc. (VKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:21 PM
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateViking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 9:26 AM
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 - PR Newswire (press release)Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 - PR Newswire (press release)
www.prnewswire.com - August 2 at 8:28 AM
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
finance.yahoo.com - August 2 at 8:28 AM
Viking Therapeutics, Inc. (VKTX) to Release Quarterly Earnings on TuesdayViking Therapeutics, Inc. (VKTX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
 Analysts Anticipate Viking Therapeutics, Inc. (VKTX) Will Post Earnings of -$0.19 Per Share Analysts Anticipate Viking Therapeutics, Inc. (VKTX) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 31 at 12:28 PM
Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip FractureCorporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 14 at 9:44 AM
Viking Therapeutics (VKTX) Completes Enrollment in Phase 2 Study of VK5211 - StreetInsider.comViking Therapeutics (VKTX) Completes Enrollment in Phase 2 Study of VK5211 - StreetInsider.com
www.streetinsider.com - July 13 at 11:15 AM
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip FractureViking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 12 at 8:56 AM
Viking Therapeutics (VKTX) Names Charles Rowland Jr. to Board - StreetInsider.comViking Therapeutics (VKTX) Names Charles Rowland Jr. to Board - StreetInsider.com
www.streetinsider.com - July 7 at 2:42 AM

Social Media

Financials

Chart

Viking Therapeutics (NASDAQ VKTX) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.